Risperidone-associated weight gain in children and adolescents: a retrospective chart review.
about
First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.Psychotropic-induced weight gain and potential pharmacologic treatment strategies.Posttraumatic stress disorder in male military veterans with comorbid overweight and obesity: psychotropic, antihypertensive, and metabolic medicationsWeight change during childhood acute lymphoblastic leukemia induction therapy predicts obesity: a report from the Children's Oncology Group.Treatment of the special patient with schizophrenia.Metabolic side effects of atypical antipsychotics in children: a literature review.Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents.Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.Drug-induced hyperphagia: what can we learn from psychiatric medications?759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment.Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.Antipsychotic drugs and obesity: is prolactin involved?An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder.A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders.
P2860
Q33845881-9E72A09F-6985-4D37-A7BE-3602BE53058CQ34413008-34503C53-00E6-4FA8-9A92-7F04F6510DDBQ34418639-F61DE4DE-3DCB-414A-A678-1E56E4F32240Q34795118-8123F1F9-E645-4ED1-B030-5AA537E987D5Q35007811-C2046893-066E-49D5-8833-3F806EBE8732Q35236370-B89D0F98-743B-4FCF-98F1-FF1679891528Q36258561-D4BC9901-8F9F-4134-AD49-533C88B9EC31Q36270899-8A55A772-D79B-4F03-AA7A-2232C3935CE8Q36956632-B741B938-9578-44A0-BA0D-891E1338F679Q37254782-53DB0E9B-17A4-41E4-B4FE-4096567B8FE0Q37719385-BD8BE8EB-9E59-4DF9-A184-DF2054B8CE08Q38090490-33E574F3-BE33-4A01-A188-E62208E5EE65Q38824837-5286737B-292B-45EE-9013-D63864BECCF7Q40669926-226BCA00-6F48-4213-B9A2-924048359472Q42092067-305EE18D-D6E4-4E8A-9AE5-6EAFAED33F71Q44635621-FBFCA1A6-1F9C-4850-B1D9-E1AD8985D1AFQ44945757-416FA3B5-9CC8-4D40-8B1F-89B53FFEAC99
P2860
Risperidone-associated weight gain in children and adolescents: a retrospective chart review.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Risperidone-associated weight ...... a retrospective chart review.
@ast
Risperidone-associated weight ...... a retrospective chart review.
@en
Risperidone-associated weight ...... a retrospective chart review.
@nl
type
label
Risperidone-associated weight ...... a retrospective chart review.
@ast
Risperidone-associated weight ...... a retrospective chart review.
@en
Risperidone-associated weight ...... a retrospective chart review.
@nl
prefLabel
Risperidone-associated weight ...... a retrospective chart review.
@ast
Risperidone-associated weight ...... a retrospective chart review.
@en
Risperidone-associated weight ...... a retrospective chart review.
@nl
P2093
P356
P1476
Risperidone-associated weight ...... a retrospective chart review.
@en
P2093
Cicchetti D
Leckman JF
P304
P356
10.1089/CAP.2000.10.259
P577
2000-01-01T00:00:00Z